What is the primary objective of FDA 21 CFR Part 11?

FDA 21 CFR Part 11 sets criteria for electronic records and signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It ensures authenticity, integrity, and non-repudiation through controls like audit trails, access limits, and signature linking in closed/open systems.

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

Organizations using electronic records/signatures under FDA predicate rules must comply with 21 CFR Part 11. This includes pharmaceutical, biotech, medical device firms, CROs/CMOs maintaining records for GxP activities like batch release, stability data, or submissions to FDA.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal validation, SOPs, and evidence during FDA inspections; predicate rules remain enforceable.

How often should an assessment for FDA 21 CFR Part 11 be performed?

Assessments for 21 CFR Part 11 compliance should occur periodically via change control, annual reviews, and before inspections. Risk-based revalidation follows system changes; audit trail reviews are quarterly, access reviews semi-annually per best practices.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with 21 CFR Part 11 can result in FDA Form 483 observations, warning letters, product holds, recalls, or injunctions. Data integrity failures often lead to invalidated records, enforcement actions, and fines tied to predicate rule violations.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, 21 CFR Part 11 aligns with frameworks like EU Annex 11, GAMP 5, and ICH guidelines on data integrity. Common mappings include audit trails (ALCOA+), validation (risk-based CSV), and electronic signatures for global harmonization.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step is conducting a risk-based scope assessment mapping predicate rules to electronic records and systems. Document reliance decisions (electronic vs. paper), classify as closed/open, and prioritize high-impact systems for validation.

What is the primary objective of 23 NYCRR 500?

23 NYCRR Part 500 safeguards nonpublic information and operational integrity of New York financial services entities. Adopted in 2017 with 2023 amendments, it mandates risk-based cybersecurity programs, governance, technical controls like MFA and encryption, TPSP oversight, testing, and rapid incident reporting to counter threats from nation-states and criminals.

Who is legally or professionally required to comply with 23 NYCRR 500?

Covered Entities licensed under NY Banking, Insurance, or Financial Services Law must comply. This includes state-chartered banks, insurers, mortgage brokers, HMOs, virtual currency licensees, and NY branches of foreign banks handling NPI; Class A Companies face enhanced rules based on >$20M NY revenue combined with either >2,000 employees or >$1B global revenue.

Does 23 NYCRR 500 require an external audit or third-party certification?

No external audit or certification is required for most entities, but Class A Companies need independent audits. NYDFS conducts examinations; entities retain five-year evidence for annual CEO/CISO certification or noncompliance acknowledgment filed by April 15, with TPSP oversight including audit rights in contracts.

How often should an assessment for 23 NYCRR 500 be performed?

Risk assessments must be conducted annually and updated upon material changes. Section 500.9 requires documented evaluations of systems, threats, vulnerabilities, and controls using frameworks like NIST CSF; integrated with enterprise risk management and informing program design, testing, and remediation.

What are the consequences of non-compliance with 23 NYCRR 500?

Non-compliance triggers multimillion-dollar fines, consent orders, and remediation mandates. NYDFS enforcement includes penalties up to $75,000/day for reckless violations (e.g., Robinhood $30M, OneMain $4.25M); governance failures, weak TPSP oversight, and MFA gaps are common citations leading to operational restrictions and reputational harm.

Can 23 NYCRR 500 be mapped to other international frameworks?

Yes, 23 NYCRR 500 aligns closely with NIST CSF, CRI Profile, and ISO 27001. Its risk-based program, controls (MFA, encryption, pen testing), and governance map to these for integrated compliance; DFS accepts equivalent methodologies documented in risk assessments.

What is the first step to begin implementing 23 NYCRR 500?

Determine Covered Entity status and appoint a qualified CISO with board access. Use NYDFS exemption flowchart, conduct initial risk assessment on critical assets/TPSPs, and build evidence repository; follow phased roadmap starting with policy approval and MFA prioritization.

Standards Comparison

FDA 21 CFR Part 11 vs 23 NYCRR 500

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation equating electronic records to paper equivalents

23 NYCRR 500

Mandatory

2017

NY regulation for financial services cybersecurity

Quick Verdict

FDA 21 CFR Part 11 ensures electronic records/signatures trust for life sciences, while 23 NYCRR 500 mandates broad cybersecurity for NY financial firms. Pharma adopts Part 11 for FDA compliance; banks use 500 to avoid DFS fines and protect NPI.

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Establishes electronic records/signatures equivalent to paper/handwritten
Mandates secure, time-stamped audit trails for changes
Requires unique, non-repudiable electronic signatures with manifestation
Differentiates controls for closed vs. open systems
Enforces validation, access limits, and authority checks

Financial Services

23 NYCRR 500

23 NYCRR Part 500 Cybersecurity Regulation

Cost

€€€€

Complexity

High

Implementation Time

18-24 months

Key Features

Annual CEO/CISO dual compliance certification
72-hour cybersecurity incident notification to NYDFS
Mandated MFA for all information system access
Risk-based TPSP security policy and contracts
Annual penetration testing and vulnerability management

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. The risk-based approach narrows scope to relied-upon electronic records, with enforcement discretion for validation, audit trails, retention, and copies per 2003 guidance.

Key Components

**Subpart BControls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits, checks, signatures manifestation/linking.
**Subpart CElectronic signature requirements (§§11.50-11.300) for uniqueness, multi-component controls, non-repudiation.
Core principles: authenticity, integrity, confidentiality, accountability. No fixed control count; focuses on 11+ key controls like training, policies.
Compliance via self-assessment, FDA inspection; no third-party certification.

Why Organizations Use It

Mandated for life sciences using electronic records; ensures data integrity for inspections, avoids warning letters. Benefits: inspection readiness, quality decisions, efficiency. Builds trust, reduces recalls, supports digital transformation.

Implementation Overview

Risk-based: scope records, classify systems, validate (CSV/IQ/OQ/PQ), implement controls, train, SOPs. Applies to pharma, devices, biotech; phased (6-24+ months). FDA audits via inspections.

23 NYCRR 500 Details

What It Is

23 NYCRR Part 500 is the New York Department of Financial Services (NYDFS) Cybersecurity Regulation, a prescriptive state-level mandate for financial services entities. It establishes minimum risk-based cybersecurity requirements to protect nonpublic information (NPI) and ensure operational integrity, applying to Covered Entities like banks, insurers, and mortgage firms licensed in New York.

Key Components

14 core requirements including cybersecurity program, CISO governance, MFA, encryption, TPSP oversight, penetration testing, and 72-hour incident reporting.
Risk-based approach with annual assessments, dual CEO/CISO certification by April 15, and five-year record retention.
Enhanced rules for Class A Companies (e.g., >$20M NY revenue, >2,000 employees) like independent audits and EDR.

Why Organizations Use It

Mandatory compliance avoids multimillion-dollar fines (e.g., Robinhood $30M).
Reduces cyber risk, improves resilience, and builds stakeholder trust.
Aligns with enterprise risk management for competitive edge.

Implementation Overview

Phased roadmap: gap analysis, asset inventory, MFA rollout, TPSP contracts, testing.
Applies to NY-licensed financial entities; no third-party certification but annual compliance filing and DFS examinations.

Key Differences

Aspect	FDA 21 CFR Part 11	23 NYCRR 500
Scope	Electronic records/signatures trustworthiness	Broad cybersecurity program and NPI protection
Industry	Life sciences, pharma, medical devices (US)	NY financial services entities (state-specific)
Nature	Mandatory FDA regulation with enforcement discretion	Mandatory state regulation with active enforcement
Testing	Risk-based system validation (IQ/OQ/PQ)	Annual pen testing, bi-annual vulnerability scans
Penalties	Warning letters, product holds, CGMP violations	Multi-million fines, consent orders, license actions

Scope

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness

23 NYCRR 500

Broad cybersecurity program and NPI protection

Industry

FDA 21 CFR Part 11

Life sciences, pharma, medical devices (US)

23 NYCRR 500

NY financial services entities (state-specific)

Nature

FDA 21 CFR Part 11

Mandatory FDA regulation with enforcement discretion

23 NYCRR 500

Mandatory state regulation with active enforcement

Testing

FDA 21 CFR Part 11

Risk-based system validation (IQ/OQ/PQ)

23 NYCRR 500

Annual pen testing, bi-annual vulnerability scans

Penalties

FDA 21 CFR Part 11

Warning letters, product holds, CGMP violations

23 NYCRR 500

Multi-million fines, consent orders, license actions

Frequently Asked Questions

Common questions about FDA 21 CFR Part 11 and 23 NYCRR 500

FDA 21 CFR Part 11 FAQ

23 NYCRR 500 FAQ

You Might also be Interested in These Articles...

Decoding Tomorrow's Regulations: How Advanced Compliance Tools Predict and Prepare for Future Shifts

Advanced compliance tools use AI, analytics & real-time monitoring to predict regulatory shifts, cut non-compliance costs 3x, and ensure audit readiness. Stay p

You Guide on how to Start Implementing NIS2 in Your Organization

Master NIS2 implementation with our detailed guide. Learn requirements, risk assessment, supply chain security, and compliance steps for your organization. Star

The Panoramic View: How Integrated Compliance Monitoring Creates Unprecedented Organizational Visibility and Adaptability

Gain unprecedented organizational visibility with integrated compliance monitoring. Automate real-time alerts, ensure GDPR & SOC 2 adherence, reduce risks, and

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how FDA 21 CFR Part 11 and 23 NYCRR 500 compare against other standards

Other FDA 21 CFR Part 11 Comparisons

Other 23 NYCRR 500 Comparisons

What It Is

Key Components

**Subpart BControls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits, checks, signatures manifestation/linking.

**Subpart CElectronic signature requirements (§§11.50-11.300) for uniqueness, multi-component controls, non-repudiation.

Core principles: authenticity, integrity, confidentiality, accountability. No fixed control count; focuses on 11+ key controls like training, policies.

Compliance via self-assessment, FDA inspection; no third-party certification.

What It Is

Key Components

14 core requirements including cybersecurity program, CISO governance, MFA, encryption, TPSP oversight, penetration testing, and 72-hour incident reporting.

Risk-based approach with annual assessments, dual CEO/CISO certification by April 15, and five-year record retention.

Enhanced rules for Class A Companies (e.g., >$20M NY revenue, >2,000 employees) like independent audits and EDR.

Aspect

FDA 21 CFR Part 11

23 NYCRR 500

Scope

Electronic records/signatures trustworthiness

Broad cybersecurity program and NPI protection

Industry

Life sciences, pharma, medical devices (US)

NY financial services entities (state-specific)

Nature

Mandatory FDA regulation with enforcement discretion

Mandatory state regulation with active enforcement

Testing

Risk-based system validation (IQ/OQ/PQ)

Annual pen testing, bi-annual vulnerability scans

Penalties

Warning letters, product holds, CGMP violations

Multi-million fines, consent orders, license actions